The week's news, read across the market. One argument a week, across companies and sectors, built from filings and public data, every figure sourced.
Thirty-two companies outside health care now mention GLP-1 drugs in their annual reports. Eighteen say the drugs may hurt them. Three say they did. The difference is the whole story.